Replies to post #121 on Equity Field Notes from temporal sources

[DanWebzster]

IONS has apetite for marketing the fruits of its research

AKCA is its affiliate public company responsible for marketing some of IONS therapies. The relationship between AKCA and IONS is fairly byzantine.

IONS has $1B in cash plus recurring revs EOY 2017

received $113mn from BIIB in 2017 for Spinraza royalties

Expenses for FY/2017 were $397mn

guided for $800mn cash EOY/18

Volanesorsen has an AdCom 5/10/18 and PDUFA 8/30/18

Inotersen has a PDUFA 7/6/18

AKCA will be responsiblie for marketing Volanesorsen and Inotersen.

Both PFE & ALNY will likely soon be marketing competing compounds to Inotersen

The long-term value of IONS is primarily in its pipeline, particularly in neural pipeline.